Holen Sie sich die Stockscreener-App
8.4029
1.21%
0.1029
Schlusskurs vom Vortag:
$8.30
Offen:
$8.26
24-Stunden-Volumen:
807.54K
Relative Volume:
0.55
Marktkapitalisierung:
$834.10M
Einnahmen:
$84.28M
Nettoeinkommen (Verlust:
$-171.30M
KGV:
-4.8368
EPS:
-1.7373
Netto-Cashflow:
$-171.21M
1W Leistung:
+7.49%
1M Leistung:
-7.28%
6M Leistung:
-18.21%
1J Leistung:
-34.37%
1-Tages-Spanne:
$8.205
$8.51
1-Wochen-Bereich:
$7.72
$8.51
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.40 | 824.17M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Update Recap: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
Roth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy Recommendation - MSN
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction - The Globe and Mail
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Profit Recap: Will ARS Pharmaceuticals Inc stock recover after earnings2026 Closing Moves & Weekly High Return Stock Opportunities - baoquankhu1.vn
ARS Pharma gains FDA clearance to remove age restriction from Neffy - MSN
Millennium-linked holders report 6.0% stake in ARS (NASDAQ: SPRY) - Stock Titan
Movement Recap: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Millennium Management LLC's Strategic Acquisition of ARS Pharmac - gurufocus.com
Millennium Management LLC's Strategic Acquisition of ARS Pharmaceuticals Inc Shares - GuruFocus
FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine - Pharmacy Times
William Blair reiterates Outperform on ARS Pharma stock after FDA label update - Investing.com UK
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - The Manila Times
Age Requirement Removed for Neffy 1mg Dose in Anaphylaxis Treatment - Medical Professionals Reference
ARS Pharma rises after Japan nod for neffy nasal spray for allergy - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8%Should You Buy? - MarketBeat
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - Barchart.com
Asthma Market: High-Growth Opportunities for Investors to 2034 - openPR.com
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
Millennium Managers Hold 5.4% of ARS Pharmaceuticals (NASDAQ: SPRY) - Stock Titan
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7%Time to Sell? - MarketBeat
(SPRY) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Will ARS Pharmaceuticals Inc stock recover after earnings2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Update Report: Can ARS Pharmaceuticals Inc sustain earnings growthBond Market & Community Verified Trade Signals - baoquankhu1.vn
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals - National Today
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Can ARS Pharmaceuticals Inc stock outperform in a bear market2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
Institution Moves: What analysts say about ARS Pharmaceuticals Inc stock2026 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Guidance Update: Is ARS Pharmaceuticals Inc a top pick in the sectorProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
[ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
SPRY: Expanding neffy access and advancing urticaria trials drive growth, with strong global uptake - TradingView
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Leerink raises ARS Pharmaceuticals stock price target on sales expansion - Investing.com Australia
Leerink raises ARS Pharmaceuticals stock price target on sales expansion By Investing.com - Investing.com Canada
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises - Investing.com India
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ars Pharmaceuticals Inc-Aktie (SPRY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dorsey Brian | Chief Operating Officer |
Nov 13 '25 |
Sale |
8.71 |
21,828 |
190,050 |
10,789 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Option Exercise |
0.84 |
30,000 |
25,200 |
166,380 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Sale |
8.87 |
166,380 |
1,476,147 |
0 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):